Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced vs Usual Intralipid for Bilirubin Neurotoxicity in Preterm Infants
NCT04584983Phase 2Active, not recruiting
- Sponsor
- UTHealth Houston
- Start
- Feb 2021
- Primary completion
- Mar 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Intralipid 10% in bilirubin encephalopathy (BIND) (2 arms), sponsored by UTHealth Houston. Primary endpoints: Number of Patients With Unbound Bilirubin Concentration Greater Than 30 Nanomoles Per Liter at 14 days, Average Unbound Bilirubin Concentration at 14 days and 1 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
Intralipid 10%
03
Conditions
bilirubin encephalopathy (BIND)
Beyond the preview
Go deeper on NCT04584983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584983.